Calciphylaxis is a rare disease with a very high mortality rate (over 80%) affecting between 1 and 4% of dialysis patients. The average life expectancy is only one year from diagnosis and it has a huge impact on the quality of life of patients, with painful ulcers and gangrene in the extremities, nodules under the skin, infarcts, etc.

Calciphylaxis has its origin in massive cardiovascular calcification of small peripheral blood vessels and there are currently no approved drugs for its treatment, so only symptoms such as pain or wounds caused are treated.

Sanifit Laboratories has received approval from the UK authorities to initiate human trials to test its lead compound against calciphylaxis. The compound, a potent inhibitor of calcification processes, has been shown to be effective in different animal models of the disease and first results are expected by the end of the year, although a product accessible to patients cannot be considered until at least 2018.

Sanifit licensed its first product in 2013 based on the same scientific principles against calcification to one of the leading pharmaceutical laboratories to treat dental calcifications (tartar) through its use in toothpastes and mouthwashes.

Laboratorios Sanifit is a Spanish biopharmaceutical company based in Palma de Mallorca and Zurich dedicated since 2007 to the discovery and development of compounds against pathologies related to tissue and organ calcifications. Funded by the venture capital instruments of "la Caixa" since its inception, the company is owned by Caixa Capital Risc and several business angels.